Scholarlink

Background <p>Currently, data concerning the prognostic impact of metastatic sites in biliary tract cancers (BTC) are limited.</p> Objective <p>The aim of the present study is to evaluate the prognostic impact of metastatic sites in patients with BTC treated with cisplatin–gemcitabine–durvalumab (CGD).</p> Patients and Methods <p>The study population comprised a large worldwide cohort of patients treated with CGD. The primary objectives were overall survival (OS) and progression-free survival (PFS) based on the location and number of metastatic sites.</p> Results <p>A total of 666 patients with locally advanced (111) or metastatic (555) BTC treated with CGD were included in the study. None of the metastatic sites were shown to have a prognostic impact on OS at multivariate analysis. Patients with one to two metastatic sites had longer OS (hazard ratio [HR] 0.59; <i>p</i> = 0.005) and PFS (HR 0.73; <i>p</i> = 0.03) compared with those with three to five metastatic sites in the univariate analysis but not in the multivariate analysis. No statistically significant differences were observed in OS or PFS across different metastatic sites limited to a single organ. Patients with progressive disease (PD) on first-line CGD with a change in metastatic sites from baseline showed no statistically significant differences in OS2 (defined as the time from PD on first-line therapy to death for any cause) compared with those without a change in metastatic sites (HR 0.88; <i>p</i> = 0.60).</p> Conclusions <p>Our study did not show statistically significant differences in outcomes associated with location and number of metastatic sites in a large population of patients with BTC treated with CGD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab

  • 期刊论文

  • 发表日期：

    2026年2月27日

查看全文
  • Silvia Camera,
  • Lorenzo Fornaro,
  • Margherita Rimini,
  • Mara Persano,
  • Mario Domenico Rizzato,
  • Anna Saborowski,
  • Lorenzo Antonuzzo,
  • Federico Rossari,
  • Tomoyuki Satake,
  • Frederik Peeters,
  • Francesca Salani,
  • Silvia Bozzarelli,
  • Salvatore Corallo,
  • Jessica Lucchetti,
  • Jin Won Kim,
  • Oluseyi Abidoye,
  • Ilario Giovanni Rapposelli,
  • Chiara Gallio,
  • Stefano Tamberi,
  • Fabian Finkelmeier,
  • Guido Giordano,
  • Pircher Chiara,
  • Hong Jae Chon,
  • Chiara Braconi,
  • Aitzaz Qaisar,
  • Alessandro Pastorino,
  • Florian Castet,
  • Emiliano Tamburini,
  • Changhoon Yoo,
  • Alessandro Parisi,
  • Anna Diana,
  • Mario Scartozzi,
  • Gerald W. Prager,
  • Antonio Avallone,
  • Marta Schirripa,
  • Il Hwan Kim,
  • Lukas Perkhofer,
  • Ester Oneda,
  • Monica Verrico,
  • Nuno Couto,
  • Jorge Adeva,
  • Stephen L. Chan,
  • Gian Paolo Spinelli,
  • Nicola Personeni,
  • Ingrid Garajova,
  • Maria Grazia Rodriquenz,
  • Silvana Leo,
  • Cecilia Melo Alvim,
  • Ricardo Roque,
  • Giovanni Farinea,
  • Virginia Genovesi,
  • Antonio De Rosa,
  • Daniele Lavacchi,
  • Federica Lo Prinzi,
  • Laura Passeri,
  • Michele Ferrara,
  • Silvia Foti,
  • Masafumi Ikeda,
  • Jeroen Dekervel,
  • Monica Niger,
  • Rita Balsano,
  • Giuseppe Tonini,
  • Minsu Kang,
  • Giulia Tesini,
  • Luca Esposito,
  • Chiara Casadio,
  • Vera Himmelsbach,
  • Matteo Landriscina,
  • Selma Ahcene Djaballah,
  • Tanios Bekaii-Saab,
  • Gianluca Masi,
  • Arndt Vogel,
  • Sara Lonardi,
  • Caterina Vivaldi,
  • Lorenza Rimassa,
  • Andrea Casadei-Gardini

摘要

Background

Currently, data concerning the prognostic impact of metastatic sites in biliary tract cancers (BTC) are limited.

Objective

The aim of the present study is to evaluate the prognostic impact of metastatic sites in patients with BTC treated with cisplatin–gemcitabine–durvalumab (CGD).

Patients and Methods

The study population comprised a large worldwide cohort of patients treated with CGD. The primary objectives were overall survival (OS) and progression-free survival (PFS) based on the location and number of metastatic sites.

Results

A total of 666 patients with locally advanced (111) or metastatic (555) BTC treated with CGD were included in the study. None of the metastatic sites were shown to have a prognostic impact on OS at multivariate analysis. Patients with one to two metastatic sites had longer OS (hazard ratio [HR] 0.59; p = 0.005) and PFS (HR 0.73; p = 0.03) compared with those with three to five metastatic sites in the univariate analysis but not in the multivariate analysis. No statistically significant differences were observed in OS or PFS across different metastatic sites limited to a single organ. Patients with progressive disease (PD) on first-line CGD with a change in metastatic sites from baseline showed no statistically significant differences in OS2 (defined as the time from PD on first-line therapy to death for any cause) compared with those without a change in metastatic sites (HR 0.88; p = 0.60).

Conclusions

Our study did not show statistically significant differences in outcomes associated with location and number of metastatic sites in a large population of patients with BTC treated with CGD.